Poop Transplants Beat Placebo for Ulcerative Colitis: What a 14-Trial Meta-Analysis Found

Ulcerative colitis affects millions of people worldwide, and its global prevalence is climbing fastest in newly industrialized countries where westernized diets and lifestyles are disrupting gut microbial ecosystems. Standard treatments, ranging from aminosalicylates to biologics, keep many patients in remission but leave a substantial share still searching for relief. Now, a systematic review and meta-analysis published in Cureus by Amal Ahad and colleagues offers the clearest RCT-based picture yet of where fecal microbiota transplantation (FMT) stands as a UC therapy.

FMT Raises Clinical Remission Rates 55% Over Placebo

Across 14 randomized controlled trials enrolling 600 patients, FMT consistently outperformed placebo for the outcomes that matter most to patients and gastroenterologists. The pooled risk ratio for clinical remission was 1.55 (95% CI 1.22 to 1.96; p = 0.0003), meaning patients who received FMT were 55% more likely to achieve clinical remission than those who received a sham procedure. Endoscopic remission, the harder standard that requires visible healing of the colon lining under a camera, showed an even larger effect: a pooled risk ratio of 1.68 (95% CI 1.15 to 2.46; p = 0.007). When combined clinical and endoscopic remission was assessed, prior research on FMT in UC RCTs has similarly found significantly higher odds in FMT-treated patients, and the Ahad et al. analysis confirmed this with an odds ratio of 2.25 (95% CI 1.54 to 3.3; p < 0.0001).

Why Delivery Method and Donor Strategy Change the Odds

Not all FMT protocols are equal, and the meta-regression results in this analysis make that concrete. Oral capsule delivery was associated with higher odds of remission compared to other routes, with an odds ratio of 3.15. Using pooled donors rather than a single donor pushed that figure even higher, to an odds ratio of 3.32. The pooled-donor advantage likely reflects microbiome diversity: a single donor may lack specific bacterial taxa that a given patient needs, while a consortium of donors improves the probability of engrafting a more complete, functional community. Pre-treatment also mattered. Patients who received methotrexate, steroids, or biologics before undergoing FMT showed a higher likelihood of remission on meta-regression, suggesting that reducing baseline inflammation before the transplant may prime the gut for successful microbial colonization.

How the Analysis Was Built on 14 RCTs

The Ahad et al. team searched PubMed, Scopus, Google Scholar, and ClinicalTrials.gov to identify every eligible randomized controlled trial. From 14 included studies, they extracted data on 600 patients, 55.8% male with a median age of 40.7 years, of whom 299 received active FMT. Primary outcomes were clinical and endoscopic remission; adverse events were tracked as secondary outcomes. Pooled risk ratios and odds ratios were calculated with 95% confidence intervals, and heterogeneity was evaluated using the I² statistic and Cochran's Q test. The focus on RCTs alone is methodologically important: double-blind RCT designs have been shown to be the gold standard for establishing FMT efficacy because they eliminate the well-documented placebo response in UC, which can run as high as 30% in some trials.

The Safety Signal Is Reassuring But Incomplete

One of the persistent concerns about FMT is safety, particularly given that the procedure involves introducing live microbial material from a donor into a patient with a compromised colonic barrier. The meta-analysis found that adverse event incidence was comparable between FMT and control groups, with a risk ratio of 0.88 (95% CI 0.77 to 1.00; p = 0.06), a result that sits just at the edge of statistical significance in a favorable direction. That is broadly reassuring, but as reviews of FMT challenges and variable results in UC have noted, long-term safety data remain thin, and the heterogeneity in how FMT is prepared, how donors are screened, and how the material is delivered makes cross-trial comparisons difficult. The field also still lacks consensus on whether FMT should be regulated as a tissue transplant or a pharmacological agent, a distinction that affects everything from donor screening requirements to trial design, as ongoing debates about FMT standardization illustrate.

What Needs to Happen Before FMT Reaches Standard Care

The Ahad et al. analysis is explicit about the path forward: larger trials with longer follow-up periods, standardized protocols for donor selection and material preparation, and mechanistic studies that explain why some patients respond and others do not. The remission signal is real and reproducible across 14 trials spanning hundreds of patients, but effect sizes and protocols vary enough that no single recipe has emerged. Future FMT research priorities center on exactly these gaps, including optimizing donor matching and building the regulatory frameworks that would allow FMT to move from experimental use to a guideline-backed option. For UC patients who have cycled through aminosalicylates and biologics without achieving stable remission, that transition cannot come soon enough. The meta-analysis puts a number on the promise: a 55% lift in clinical remission and a 68% lift in endoscopic remission over placebo. Now the field needs the protocols to deliver it reliably.

Evidence rating

ESTABLISHED — 90/100

Caveats:

• Protocols varied widely across included trials — donor selection, delivery route, and dosing were not standardized, limiting direct comparisons.
• Funding was not disclosed by the authors, so potential conflicts of interest cannot be fully assessed.
• Long-term durability of remission remains unclear; most included trials had limited follow-up periods.
• Mechanistic detail is limited — how FMT restores immune homeostasis at the species or metabolite level is not fully characterized in this analysis.

Systematic review and meta-analysis of randomized controlled trials. Pooled results across multiple independent RCTs show statistically significant benefits for both clinical remission (RR 1.55) and endoscopic remission (RR 1.68), supporting a causal inference stronger than single-study findings. Heterogeneity in donor selection, delivery route, and treatment protocols across included trials limits generalizability, and long-term outcomes remain insufficiently characterized.

References

1. Amal Ahad, Sandeep Kumar, Hugh Kolomar, et al. (2026). Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). Cureus. https://doi.org/10.7759/cureus.111804
2. R. Gefen, J. Dourado, S. H. Emile, et al. (2025). Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials. Techniques in Coloproctology. https://doi.org/10.1007/s10151-025-03113-7
3. Efficacy of Fecal Microbiota Transplantation in the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials – PubMed. NIH. https://pubmed.ncbi.nlm.nih.gov/37130282/
4. Jinghong Liu, Xiaojuan Wu (2026). Fecal microbiota transplantation in ulcerative colitis: evidence, mechanisms, and practice considerations. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/17562848261426284
5. Perspective: on the future of fecal microbiota transplantation – Frontiers. frontiersin.org. https://www.frontiersin.org/articles/10.3389/fcimb.2023.1160321/full
6. Ra Ri Cha, Irene Sonu (2025). Fecal microbiota transplantation: present and future. Clinical Endoscopy. https://doi.org/10.5946/ce.2024.270